Jin et al. revealed that miR-22-3p targets KDM3A to regulate YAP1 expression to exert anti-tumor effects, suggesting that KDM3A regulates the Hippo signaling pathway to promote CRC progression [119]. Here, YAP1 is linked to neoplasm.